Trial Profile
A Registrational Trial Investigating CK-301 as First-Line Treatment in Patients with Non-Small Cell Lung Cancer
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 27 Mar 2018
Price :
$35
*
At a glance
- Drugs Cosibelimab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Checkpoint Therapeutics
- 27 Mar 2018 New trial record
- 21 Mar 2018 According to Checkpoint Therapeutics media release, company is expecting to initiat this trial in the first quarter of 2019